Immune checkpoint inhibitors have demonstrated significant efficacy in the treatment of a
variety of cancers, however their therapeutic potential is limited by abstruse immune related …

Checkpoint blockade immunotherapies can be extraordinarily effective, but might benefit
only the minority of patients whose tumors are pre-infiltrated by T cells. Here, using lung …

Cancer immunotherapy has transformed the treatment of cancer. However, increasing use of
immune-based therapies, including the widely used class of agents known as immune …

Cancer immunotherapy using antibodies that target immune checkpoints has delivered
outstanding results. However, responses only occur in a subset of patients, and it is not fully …

The immune system has the potential to recognize and eliminate tumor cells, and failed
immune surveillance contributes to cancer development. Many immunotherapeutics …

Even though the discovery of immune checkpoint inhibitors (ICIs) has revolutionized cancer
treatment, a high proportion of patients do not respond. Moreover, some types of cancers are …

Cancer immunotherapy, which leverages features of the immune system to target neoplastic
cells, has revolutionized the treatment of cancer. The use of these therapies has rapidly …

Cancer is still the leading cause of death globally. The approval of the therapeutic use of
monoclonal antibodies against immune checkpoint molecules, notably those that target the …

Immune checkpoint inhibitors (ICIs) are novel class of anti-cancer drugs that exhibit
significant therapeutic effects even in patients with advanced-stage cancer. However, the …

Immune checkpoint blockade (ICB) has revolutionized cancer treatment. However,
resistance to ICB occurs frequently due to tumor-intrinsic alterations or extrinsic factors in the …